R. Mondola, S. Magara, A. Eramo, A. De Bartolomeis - Vol. 10, September 2004, Issue 3
Testo Bibliografia Summary Indice
Terapia di potenziamento degli antipsicotici
con farmaci non convenzionali nel trattamento della schizofrenia
Augmentation therapy of antipsychotics by no conventional drugs in
schizophrenia treatment
Augmentation of antipsychotics by compounds not used conventionally in psychiatry therapy has been recently suggested for the treatment of resistant schizophrenia. Here we review the combination therapy of antipsychotics with: glutamatergic agonists (glycine, D-cycloserine, D-serine), glycine transporter-inhibitors (sarcosine), a-adrenergic (idazoxan), serotoninergic (cyproeptadin), histaminergic (famotidine) antagonists, MAO-inhibitors (deprenyl), oppioid antagonists (naltrexone), COX-inhibitors (celecoxib), fatty acids (ethyl-eicosapentaenoic acid), antioxidants, deidroepyandrosterone. The interpretation of these studies requires caution due to the sperimental setting and the number of patients involved, however they suggest new strategies for the treatment of resistant schizophrenia and point to new putative correlates in the pathophysiology of the disorder.